Clofarabine: Past, present, and future

References

• Lotfi K, Mansson E, Spasokoukotskaja T, Pettersson B, Liliemark J, Peterson C, et al. Biochemical pharmacology and resistance to 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin Cancer Res 1999; 5: 2438–2444
   PubMed Web of Science ®Google Scholar
• Carson D, Wasson D, Esparza L, Carrera C, Kipps T, Cottam H. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine. Proc Natl Acad Sci USA 1992; 89: 2970–2974
   PubMed Web of Science ®Google Scholar
• Parker W, Shaddix S, Rose L, Shewach D S, Hertel L W, Secrist J A, et al. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-β-d-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-β-d-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro-β-d-ribofuranosyl)adenine in CEM Cells. Mol Pharmacol 1998; 55: 515–520
   Web of Science ®Google Scholar
• Eriksson S, Arner E, Spasokoukotskaja T, Wang L, Karlsson A, Brosjo O, et al. Properties and levels of deoxynucleoside kinases in normal and tumor cells; implications for chemotherapy. Adv Enzyme Regul 1994; 34: 13–25
   PubMedGoogle Scholar
• Arner E, Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol Ther 1995; 67: 155–186
   PubMed Web of Science ®Google Scholar
• Bonate P, Arthaud L, Cantrell W, Stephenson K, Secrist J, Weitman S. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nature Rev Drug Discovery 2006; 5: 855–863
   PubMed Web of Science ®Google Scholar
• Genini D, Adachi S, Chao Q, Rose D W, Carrera C J, Cottam H B, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000; 96: 3537–3543
   PubMed Web of Science ®Google Scholar
• Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-β-d-arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res 1995; 55: 2847–2852
   PubMed Web of Science ®Google Scholar
• Qian M, Wang X, Shanmuganathan K, Chu C, Gallo J. Pharmacokinetics of the anticancer agent 2-chloro-9-(2-deoxy-2-fluoro-β-d-arabinofuranosyl)adenine in rats. Cancer Chemother Pharmacol 1994; 33: 484–488
   PubMed Web of Science ®Google Scholar
• Bonate P, Craig A, Gaynon P, Gandhi V, Jeha S, Kadota R, et al. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol 2004; 44: 1309–1322
   PubMed Web of Science ®Google Scholar
• Xie K, Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-β-d-arabinofuranosyl) adenine. Cancer Res 1996; 56: 3030–3037
   PubMed Web of Science ®Google Scholar
• Cooper T, Ayres M, Nowak B, Gandhi V. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother. Pharmacol 2005; 55: 361–368
   Web of Science ®Google Scholar
• Moufarij M, Sampath D, Keating M, Plunkett W. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood 2006; 108: 4187–4193
   PubMed Web of Science ®Google Scholar
• Warrell R P, Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 1986; 4: 74–79
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Gandhi V, Kozuch P, Faderl S, Giles F J, Cortes J, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003; 21: 1167–1173
   PubMed Web of Science ®Google Scholar
• Jeha S, Gandhi V, Chan K, McDonald L, Ramirez I, Madden R, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004; 103: 784–789
   PubMed Web of Science ®Google Scholar
• Jeha S, Gaynon P, Razzouk B, Franklin J, Kadota R, Shen V, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006; 24: 1917–1923
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003; 102: 2379–2386
   PubMed Web of Science ®Google Scholar
• Gandhi V, Kantarjian H, Faderl S, Bonate P, Du M, Ayres M, et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clinical Cancer Res 2003; 9: 6335–6342
   PubMed Web of Science ®Google Scholar
• Foran J, Faderl S, Wetzler M, Dipersio J, Rizzieri D, Kantarjian H M, et al. A phase II, open-label study of clofarabine in adult patients with refractory or relapsed acute myelogenous leukemia. Proc Am Soc Clin Oncol 2003; 22: 587, (abstract 2360)
   Google Scholar
• Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, et al. Results of a phase 1–2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory leukemias. Blood 2005; 105: 940–947
   PubMed Web of Science ®Google Scholar
• Agura E, Berryman R, Brougher L, Cooper B, DeLeon A, Fay J, et al. Phase II study of clofarabine and cytosine arabinoside in adult patients with relapsed AML and in elderly patients with untreated AML who are at high risk of anthracycline toxicity. Blood 2006; 108: 552a, (abstract 1951)
   Web of Science ®Google Scholar
• Yamauchi T, Nowak B, Keating M, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001; 7: 3580–3589
   PubMed Web of Science ®Google Scholar
• Faderl S, Ferrajoli A, Ravandi-Kashani F, Verstovsek S, Wierda W G, Borthakur G, et al. Clofarabine plus anthracycline combinations in acute myeloid leukemia (AML) salvage. Blood 2006; 108: 51a, (abstract 159)
   Web of Science ®Google Scholar
• Karp J, Ricklis R, Greer J, Briel J, Levis M. Phase I clinical-laboratory trial of clofarabine (CLO) followed by cyclophosphamide (CY) for adults with refractory acute leukemias: evidence for enhanced DNA damage. Blood 2006; 108: 555a, (abstract 1963)
   Web of Science ®Google Scholar
• Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age and older. Blood 2006; 108: 45–51
   PubMed Web of Science ®Google Scholar
• Burnett A, Russell N, Kell J, Milligan D, Culligan D. A phase 2 evaluation of single agent clofarabine as first line treatment for older patients with AML who are not considered fit for intensive chemotherapy. Blood 2004; 104: 869, (abstract)
   Google Scholar
• Burnett A, Baccarani M, Johnson P, Yin J, Saunders A, Russell N. Effectiveness of clofarabine in elderly AML patients with adverse cytogenetics unfit for intensive chemotherapy. Blood 2006; 108: 1985, (abstract)
   Google Scholar
• Faderl S, Ravandi-Kashani F, Ferrajoli A, Garcia-Manero G, Estrov Z, Thomas D A, et al. Clofarabine and clofarabine plus low-dose cytarabine (ara-C) as induction therapy for patients (pts) ≥ age 60 with newly diagnosed acute myeloid leukemia (AML). Blood 2005; 106, (abstract 2804)
   PubMed Web of Science ®Google Scholar
• Foran J, The A, Devettan M, Meleth S, Worrell J, Dixon P, et al. Phase I/II study of clofarabine combined with standard dose cytarabine as remission induction therapy of de novo AML in elderly patients ≥60 years. Blood 2005; 106, (abstract 4635)
   PubMed Web of Science ®Google Scholar
• Burnett A, Kell W, Hills R, Russell N H, Yin J, Hunter A, et al. The feasibility of combining daunorubicin, clofarabine and gemtuzumab ozogamicin is feasible and effective. A pilot study. Blood 2006; 108, (abstract 1950)
   Google Scholar
• Kantarjian H, O'Brien S, Cortes J, Giles F J, Faderl S, Jabbour E, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer 2006; 106: 1090–1098
   PubMed Web of Science ®Google Scholar
• Burnett A, Baccarani M, Johnson P, Yin J, Russell N. Clofarabine in previously untreated elderly (>65 yrs) AML patients with an unfavourable cytogenetic profile who are considered unfit for standard intensive chemotherapy. Proc Am Soc Clin Oncol 2006; 24, (abstract 6513)
   Google Scholar
• Faderl S, Ferrajoli A, Wierda W, Ravandi F, Estrov Z, Verstovsek S, et al. Clofarabine combinations in Acute Myeloid Leukemia (AML) salvage: a dose-finding phase I study of clofarabine plus idarubicin and clofarabine/idarubicin plus cytarabine (ara-C). Blood 2005; 106, (abstract 2803)
   PubMed Web of Science ®Google Scholar
• Silverman L, McKenzie D, Peterson B, Holland J F, Backstrom J T, Beach C L, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24: 3895–3903
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O'Brien S, Huang X, Garcia-Manero G, Giles F, Wierda W, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher-risk myelodysplastic syndrome – comparison to historical experience. Cancer 2007; 109: 1133–1137
   PubMed Web of Science ®Google Scholar
• Faderl S, Gandhi V, O'Brien S, Giles F J, Cortes J, Plunkett W, et al. Clofarabine is active in myelodysplastic syndrome (MDS). Blood 2006; 108, (abstract 2660)
   Google Scholar